To the Editor: According to the conclusions of Van den Berghe and colleagues (Feb. 2 issue),¹ the mortality among patients staying three days or longer in a medical intensive care unit (ICU) was significantly decreased with the use intensive insulin ...

To the Editor: We have used an approach similar to that of Remuzzi et al. (Jan. 26 issue)¹ in the assessment of kidneys from donors older than 60 years of age and the implantation of organs with minimal renal changes as assessed on biopsy before ...

To the Editor: In our opinion, the randomized clinical trial by Berry et al. (Feb. 16 issue)¹ appears to mitigate the excitement that has been generated in recent years concerning the use of tumor necrosis factor α (TNF-α) inhibitors in the management of ...

To the Editor: In the article by Lees et al. (Feb. 9 issue)¹ about the Stroke–Acute Ischemic NXY Treatment (SAINT I) trial, the abstract suggests significant reduction of hemorrhagic transformation after receipt of NXY-059, as determined by a post hoc ...

To the Editor: I am troubled by the universal enthusiasm displayed by interventional cardiologists for coronary-artery stenting — stent mania. As mentioned by Serruys et al. in their excellent review (Feb. 2 issue),¹ “stenting [with bare metal stents] ...

To the Editor: In the Case Records, Walton at al. (Feb. 16 issue)¹ elegantly discuss retinoblastoma, but their definition of leukokoria is inaccurate. Leukokoria is taken directly from the Greek and means simply “white pupil.” When the normal pupil is ...

To the Editor: Lenalidomide (Revlimid) is an analogue of thalidomide that has clinical activity in a variety of hematologic conditions.¹ It has recently been approved by the Food and Drug Administration for certain myelodysplastic syndromes associated ...